TipRanks
Advertisement
Advertisement

MX:BIIB Stock Latest News

Biogen says litifilimab demonstrates rapid, durable efficacy in Phase 2 data
The FlyBiogen says litifilimab demonstrates rapid, durable efficacy in Phase 2 data
3h ago
BIIB
Mizuho biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Mizuho biotech analysts hold an analyst/industry conference call
24h ago
BBIO
BIIB
Biogen publishes results from adolescent subgroup of VALIANT study
PremiumThe Fly
Biogen publishes results from adolescent subgroup of VALIANT study
15d ago
BIIB
Eisai, Biogen announce Leqembi Pen has been approved in Japan
PremiumThe Fly
Eisai, Biogen announce Leqembi Pen has been approved in Japan
16d ago
BIIB
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
PremiumThe Fly
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
22d ago
GS
MS
Biogen price target raised to $175 from $165 at HSBC
PremiumThe FlyBiogen price target raised to $175 from $165 at HSBC
22d ago
BIIB
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
Premium
The Fly
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
29d ago
BIIB
STOK
Biogen price target raised to $245 from $225 at Piper Sandler
Premium
The Fly
Biogen price target raised to $245 from $225 at Piper Sandler
29d ago
BIIB
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
PremiumThe Fly
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
29d ago
BIIB
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
PremiumThe Fly
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
1M ago
BIIB
STOK
Biogen, Eisai announce positive recommendation for Leqembi in Canada
PremiumThe Fly
Biogen, Eisai announce positive recommendation for Leqembi in Canada
1M ago
BIIB
Veeva price target raised to $310 from $270 at Needham
PremiumThe Fly
Veeva price target raised to $310 from $270 at Needham
1M ago
LLY
BIIB
Biogen price target raised to $260 from $240 at RBC Capital
PremiumThe FlyBiogen price target raised to $260 from $240 at RBC Capital
1M ago
BIIB
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
Premium
The Fly
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
1M ago
BIIB
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
Premium
The Fly
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
1M ago
BIIB
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
PremiumThe Fly
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
1M ago
PMN
BIIB
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe Fly
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
2M ago
BIIB
Wolfe upgrades Biogen to Outperform on late-stage pipeline
PremiumThe Fly
Wolfe upgrades Biogen to Outperform on late-stage pipeline
2M ago
BIIB
Five Below upgraded, StubHub downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Five Below upgraded, StubHub downgraded: Wall Street’s top analyst calls
2M ago
OI
ALC
Biogen completes acquisition of RayThera
PremiumThe FlyBiogen completes acquisition of RayThera
2M ago
BIIB
Biogen price target raised to $241 from $221 at Mizuho
Premium
The Fly
Biogen price target raised to $241 from $221 at Mizuho
2M ago
BIIB
Biogen price target raised to $215 from $200 at Citi
Premium
The Fly
Biogen price target raised to $215 from $200 at Citi
2M ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >